Prevalence and Reversibility of Lung Hyperinflation in Asthma

Chiesi Farmaceutici S.p.A.450 enrolled

Overview

The aim of this observational study is to evaluate the pulmonary hyperinflation and its immediate reversibility to a short acting beta2 agonist test in uncontrolled persistent asthmatic patients with dyspnea.

The other objectives are : * the evaluation of the hyperinflation defined by an increase of the residual volume (RV), * the observation of the relationship between the hyperinflation and the asthma characteristics, * the study of the improvement of the functional parameters after a reversibility test * the evaluation of the correlation between hyperinflation parameters evolution, chest tightness and dyspnea

Study Type

OBSERVATIONAL

Enrollment

450

Conditions

Asthma

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with a diagnosis of uncontrolled persistent asthma (ACT \</= 19) or with an MRC score of dyspnea \>/= 1 * Patient requiring a check-up including a pulmonary function test by plethysmography with a reversibility test Exclusion Criteria: * Patient participating to an other clinical trial or having participated to a clinical trial with medicine in the last 3 months

Locations (1)

Laboratoire Chiesi S.A.

Courbevoie, France

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.